Metsera (MTSR) Registration Filing summary

Company overview and business model

• Clinical-stage biotech focused on next-generation injectable and oral NuSH analog peptides for obesity, overweight, and related conditions.

• Proprietary platforms: MINT peptide library, HALO half-life extension, and MOMENTUM oral delivery.

• Pipeline includes clinical-stage injectable and oral GLP-1 RA analogs, an injectable amylin analog, and multiple preclinical NuSH analogs.

• Lead candidate MET-097i is a monthly, subcutaneous, ultra-long acting GLP-1 RA in Phase 2b trials.

• Business model includes internal R&D, strategic licensing, and manufacturing partnerships.

Financial performance and metrics

• Net loss of $156.3M for the nine months ended September 30, 2024; accumulated deficit of $204.3M.

• Cash and cash equivalents of $187.6M as of September 30, 2024.

• Operating expenses driven by R&D ($68.6M for nine months ended September 30, 2024) and G&A ($17.1M).

• No product revenue to date; operations funded by $321.5M in preferred stock and convertible note proceeds.

• Substantial additional capital required to fund operations and clinical development.

Use of proceeds and capital allocation

• Net proceeds from IPO to fund Phase 3 clinical trial of MET-097i through topline results and related milestones.

• Remaining proceeds allocated to working capital and general corporate purposes.

• Existing cash and IPO proceeds expected to fund operations into future periods, but not through full product development.